Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Aflibercept for the treatment of age-related macular degeneration.

Trichonas G, Kaiser PK.

Ophthalmol Ther. 2013 Dec;2(2):89-98. doi: 10.1007/s40123-013-0015-2. Epub 2013 Jun 25.

2.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups.

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
3.

Aflibercept in wet age-related macular degeneration: a perspective review.

Ohr M, Kaiser PK.

Ther Adv Chronic Dis. 2012 Jul;3(4):153-61. doi: 10.1177/2040622312446007.

4.

Aflibercept for neovascular age-related macular degeneration.

Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD.

Cochrane Database Syst Rev. 2016 Feb 8;2:CD011346. doi: 10.1002/14651858.CD011346.pub2. Review.

5.

Aflibercept for age-related macular degeneration: a game-changer or quiet addition?

Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW.

Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. Review.

PMID:
22813448
6.

Aflibercept in wet AMD: specific role and optimal use.

Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C.

Drug Des Devel Ther. 2013 Aug 5;7:711-22. doi: 10.2147/DDDT.S40215. eCollection 2013. Review.

7.

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.

Ohr M, Kaiser PK.

Expert Opin Pharmacother. 2012 Mar;13(4):585-91. doi: 10.1517/14656566.2012.658368. Epub 2012 Feb 3. Review.

PMID:
22300011
8.

Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.

Yazdi MH, Faramarzi MA, Nikfar S, Falavarjani KG, Abdollahi M.

Expert Opin Biol Ther. 2015;15(9):1349-58. doi: 10.1517/14712598.2015.1057565. Epub 2015 Jun 16. Review.

PMID:
26076760
9.

Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.

Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, Wang EC, Heier J, Kaiser P, Chong V, Korobelnik JF.

Ophthalmology. 2015 Mar;122(3):571-8. doi: 10.1016/j.ophtha.2014.09.024. Epub 2014 Nov 6.

PMID:
25439429
10.

Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.

Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M, Di Desidero T, Orlandi P, Bocci G.

Angiogenesis. 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. Epub 2015 Sep 7. Review.

PMID:
26346237
11.

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.

Stewart MW.

Clin Ophthalmol. 2012;6:1175-86. doi: 10.2147/OPTH.S33372. Epub 2012 Jul 26.

12.

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.

García-Layana A, Figueroa MS, Araiz J, Ruiz-Moreno JM, Gómez-Ulla F, Arias-Barquet L, Reiter N.

Drugs Aging. 2015 Oct;32(10):797-807. doi: 10.1007/s40266-015-0300-y. Review.

13.

Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.

Johnston SS, Wilson K, Huang A, Smith D, Varker H, Turpcu A.

Adv Ther. 2013 Dec;30(12):1111-27. doi: 10.1007/s12325-013-0078-4. Epub 2013 Dec 6. Erratum in: Adv Ther. 2014 Jan;31(1):150-1.

14.

Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.

Frampton JE.

Drugs Aging. 2013 May;30(5):331-58. doi: 10.1007/s40266-013-0077-9. Review.

PMID:
23539234
15.

Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.

Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF.

Acta Ophthalmol. 2015 Mar;93(2):e154-9. doi: 10.1111/aos.12604. Epub 2014 Dec 8.

16.

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.

Stewart MW.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):103-13. doi: 10.1586/ecp.12.81. Review.

PMID:
23473589
17.

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Zhu Y, Zhang T, Xu G, Peng L.

Cochrane Database Syst Rev. 2016 Dec 15;12:CD011160. doi: 10.1002/14651858.CD011160.pub2. Review.

PMID:
27977064
18.

Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Frampton JE.

Drugs Aging. 2012 Oct;29(10):839-46. doi: 10.1007/s40266-012-0015-2. Review.

PMID:
23038609
19.

Intravitreal aflibercept for neovascular age-related macular degeneration.

Xu D, Kaiser PK.

Immunotherapy. 2013 Feb;5(2):121-30. doi: 10.2217/imt.12.158.

PMID:
23413903
20.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS.

Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.

PMID:
24084500

Supplemental Content

Support Center